Matthew Biegler
Stock Analyst at Oppenheimer
(1.18)
# 3,603
Out of 4,902 analysts
81
Total ratings
32.39%
Success rate
-11.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $32 → $30 | $12.09 | +148.14% | 1 | Jul 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $10 → $9 | $1.32 | +581.82% | 2 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.24 | +625.81% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $4.51 | +387.80% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $11.17 | +7.48% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $2.38 | +236.13% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $7.76 | +479.90% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $108.80 | +5.70% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $22.09 | +139.93% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $10.86 | +203.87% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.44 | +1,288.89% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.65 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $129.46 | -3.45% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $12.53 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.94 | +76.32% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.30 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.15 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.50 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.00 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.20 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $5.93 | +5,970.83% | 1 | Nov 30, 2022 |
Nurix Therapeutics
Jul 10, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $12.09
Upside: +148.14%
Acrivon Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.32
Upside: +581.82%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.24
Upside: +625.81%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $4.51
Upside: +387.80%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $11.17
Upside: +7.48%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.38
Upside: +236.13%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $7.76
Upside: +479.90%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $108.80
Upside: +5.70%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $22.09
Upside: +139.93%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.86
Upside: +203.87%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.44
Upside: +1,288.89%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.65
Upside: -
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $129.46
Upside: -3.45%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $12.53
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.94
Upside: +76.32%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.30
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.15
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.50
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.00
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.20
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $5.93
Upside: +5,970.83%